Targos Team
Management
Thomas Henkel
Chief Executive Officer & Co-Founder
About
Publications
Stoss, O., Henkel, T. Role of Central Laboratories in Research, Validation, and Application of Predictive Biomarkers. Predictive Biomarkers in Oncology - Applications in Precision Medicine. 2019 Chapter 51, p 559-567 Editors Badve S and Kumar GK, Springer Nature, ISBN 978-3-319-95227-7
Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC,
Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU,
Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology. 2018
Feb;72(3):449-459. doi: 10.1111/his.13375.
Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B,
Untch M, Rüschoff J. Impact of updated HER2 testing guidelines in breast
cancer--re-evaluation of HERA trial fluorescence in situ hybridization data. Mod
Pathol. 2015 Dec;28(12):1528-34.
König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K,
Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F,
Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M,
Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U,
Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis
and Therapy of Lung Cancer Patients. J Thorac Oncol. 2015 Jul;10(7):1049-57.
Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. ErbB2 diagnostics in breast cancer--an update. Pathologe. 2009 Mar;30(2):147-55.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 Jun;52(7):797-805.
Stoss O, Werther M, Zielinski D, Middel P, Jost N, Ruschoff J, Henkel T, Albers P.
Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2):166-72; Epub 2007 Jul 24.
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M,
Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin(R)) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy., J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.
Stoss O, Jost N, Czeloth K, Ruschoff J, Henkel T, Albers P. Urologe A. 2007 Sep;46(9):1117-9.
Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J.
Her-2/neu analysis--new data? Verh Dtsch Ges Pathol. 2006; 90:107-13.
Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M._L., Palme S., Berndt P., Engel A., Pfeffer M, Karl J, Bodenmueller H, Rüschoff J, Henkel T, Rohr G., Rossol S., Rösch W., Langen H., Zolg W, and Tacke M (2006) Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis
Mol. Cell. Proteomics August 6, 2006, 10.1074/mcp.M600118-MCP200
Roessler, M., Rollinger, W., Palme, S., Hagmann, ML., Berndt, P., Engel, AM.,
Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2005)
Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clin Cancer Res. 2005 Sep 15;11(18):6550-6557.
Stoss, O. and Henkel T. (2004) Biomedical marker molecules for cancer – current status and perspectives. Drug Discovery Today Targets, 3(6), 228-237
Schmidtgen, C. and Henkel T. (2004) Gewebebanken in der Biomedizinischen Forschung. BioForum 1/04
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2003) Emerging molecular targets for chronic heart failure (Part II). Exp. Opinion Therap.Targets 7(1):pp
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2002) Emerging molecular targets for chronic heart failure (Part I). Exp.Opinion Therap.Targets 6(6):649-658
Stoss, O., Reuner, B. and Henkel, T. (2002) RNA Expression profiling in cardiac tissue – a successful route to new drug targets? Targets 1, 12-19
Nave, B.T., Becker, M., Roenicke, V., Henkel, T. (2002) Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model.
Drug Discov Today Apr 1;7(7):419-425
Funk, M., Niedenthal, R., Mumberg, D., Brinkmann, K., Rönicke, V. and Henkel, T. (2002)
Vectors systems for the heterologous expression of proteins in Saccharomyces cerevisiae. In Guide to Yeast Genetics and Molecular Cell Biology Part B, Methods in Enzymology, Vol 350: 248
Henkel, T. (1999) Therapeutic Innovation. IDrugs 2(5):403-404
Henkel, T. & Klein, H.-G. (1998) Differentielle Genexpression. Medizinische Genetik 2:356
Hsieh, J.J.D, Henkel, T., Salmon, P., Robey, E., Peterson, M.G. and Hayward, S.D. (1996) Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr Virus EBNA-2. Mol. Cell. Biol. 16, 952-959
Traenckner, E.B.M, Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S. and Baeuerle, P.A. (1995) Phosphorylation of human IκB- on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14, 2876-2883
Henkel, T., Ling, P.D., Hayward, S.D. and Peterson, M.G. (1994) Mediation of Epstein-Barr Virus EBNA2 trans-activation by Recombination Signal-Binding Protein Jκ. Science, 265, 92 - 95.
Baeuerle, P.A. and Henkel, T. (1994) Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12, 141-179.
Groß, N. A., Henkel, T., Karabinos, A., Götz, H., Barnikol-Watanabe, S. and Hilschmann, N. (1994) Human protein NEFA, a novel DNA binding/EF-hand/ leucine zipper protein - Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol. Chem. Hoppe Seyler, 375, 497-512
Machleidt, T., Wiegmann, K., Henkel, T., Schütze, S., Baeuerle, P. and Krönke, M.
(1994), Sphingomyelinase activates proteolytic IκB-a degradation in a cell-free system.
J. Biol. Chem. 269, 13760-13765
Henkel, T., Machleidt, T., Alkalay I., Krönke M., Ben-Neriah, Y. and P.A. Baeuerle
(1993) Rapid proteolysis of IκB- is necessary for activation of transcription factor NF-κB. Nature 365, 182-185
Zabel, U., Henkel, T., dos Santos Silva, M. and Baeuerle, P.A. (1993) Nuclear uptake
control of NF-κB by MAD-3, an IκB protein present in the nucleus. EMBO J. 12, 201-211
Henkel, T., Schmitz, M.L. and Baeuerle, P.A. (1993) Rapid characterization of lambda cDNA clones after amplification and radioactive labeling with the PCR technique. BioTechniques, 14 (6), 3 - 4
Henkel, T and P.A. Baeuerle (1993) Functional analysis of mutated cDNA clones by direct use of PCR products in in vitro transcription/translation reactions. Anal. Biochem. 214, 351-352
Henkel, T., Zabel, U., van Zee, K., Müller, J., Fanning, E. and Baeuerle, P.A. (1992) Intramolecular masking of the nuclear location signal and dimerization domain in the precursor of the p50 NF-κB subunit. Cell 68, 1121-1133
Ruben, S., Dillon, P.J., Schreck, R., Henkel, T., Chen, C.-H., Maher, M., Baeuerle, P.A. and Rosen C. (1991). Isolation of a rel- related human cDNA that potentially encodes the 65-kD subunit of NF-κB Science 251: 1490-1493
Method for identifying substances directed against myocardial cell hypertrophy
PCT/WO 02/097128A2 published 05.12. 2002
Inventors: T. Henkel, V. Rönicke, B. Navé
Applicant: MediGene AG
Herz- und Skelettmuskelspezifische Nukleinsäure, ihre Herstellung und Verwendung.
German Patent issued 15.6. 2000
Inventors: T. Henkel, M. Hofmann & H. Domdey
Applicant: MediGene AG
Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
PCT/EP97/02840 filed 30.05 1997
Inventors: B. Steipe, H. Bruhn, M. Funk, T. Henkel
Applicant: MediGene AG
Epstein-Barr virus transcription factor binding assay
US Patent 5,679,525 issued 21.10. 1997
Inventors: T. Henkel & M. G. Peterson
Applicant: Tularik Inc.
Process for inhibiting the transcription of genes
US Patent 6,090,542 issued 18.7. 2000
Inventors: T. Henkel & P.A. Bäuerle
Applicant: Boehringer Ingelheim International GmbH et al.
Dr. Thomas Henkel
Chief Executive Officer
Co-Foundert
Having experience as a scientist, Dr. Henkel ventured into US and German biotechnology to develop therapeutics and diagnostics. In 2005 Targos was cofounded by Dr. Henkel to meet the increasing demand for professional biomarker services. His entrepreneurial leadership and innovation management skills helped to grow Targos into a sustainable, commercially successful business.
Publications
Publications:
Stoss, O., Henkel, T. Role of Central Laboratories in Research, Validation, and Application of Predictive Biomarkers. Predictive Biomarkers in Oncology - Applications in Precision Medicine. 2019 Chapter 51, p 559-567 Editors Badve S and Kumar GK, Springer Nature, ISBN 978-3-319-95227-7
Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC,
Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU,
Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology. 2018
Feb;72(3):449-459. doi: 10.1111/his.13375.
Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B,
Untch M, Rüschoff J. Impact of updated HER2 testing guidelines in breast
cancer--re-evaluation of HERA trial fluorescence in situ hybridization data. Mod
Pathol. 2015 Dec;28(12):1528-34.
König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K,
Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F,
Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M,
Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U,
Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis
and Therapy of Lung Cancer Patients. J Thorac Oncol. 2015 Jul;10(7):1049-57.
Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. ErbB2 diagnostics in breast cancer--an update. Pathologe. 2009 Mar;30(2):147-55.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 Jun;52(7):797-805.
Stoss O, Werther M, Zielinski D, Middel P, Jost N, Ruschoff J, Henkel T, Albers P.
Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2):166-72; Epub 2007 Jul 24.
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M,
Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin(R)) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy., J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.
Stoss O, Jost N, Czeloth K, Ruschoff J, Henkel T, Albers P. Urologe A. 2007 Sep;46(9):1117-9.
Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J.
Her-2/neu analysis--new data? Verh Dtsch Ges Pathol. 2006; 90:107-13.
Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M._L., Palme S., Berndt P., Engel A., Pfeffer M, Karl J, Bodenmueller H, Rüschoff J, Henkel T, Rohr G., Rossol S., Rösch W., Langen H., Zolg W, and Tacke M (2006) Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis
Mol. Cell. Proteomics August 6, 2006, 10.1074/mcp.M600118-MCP200
Roessler, M., Rollinger, W., Palme, S., Hagmann, ML., Berndt, P., Engel, AM.,
Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2005)
Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clin Cancer Res. 2005 Sep 15;11(18):6550-6557.
Stoss, O. and Henkel T. (2004) Biomedical marker molecules for cancer – current status and perspectives. Drug Discovery Today Targets, 3(6), 228-237
Schmidtgen, C. and Henkel T. (2004) Gewebebanken in der Biomedizinischen Forschung. BioForum 1/04
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2003) Emerging molecular targets for chronic heart failure (Part II). Exp. Opinion Therap.Targets 7(1):pp
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2002) Emerging molecular targets for chronic heart failure (Part I). Exp.Opinion Therap.Targets 6(6):649-658
Stoss, O., Reuner, B. and Henkel, T. (2002) RNA Expression profiling in cardiac tissue – a successful route to new drug targets? Targets 1, 12-19
Nave, B.T., Becker, M., Roenicke, V., Henkel, T. (2002) Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model.
Drug Discov Today Apr 1;7(7):419-425
Funk, M., Niedenthal, R., Mumberg, D., Brinkmann, K., Rönicke, V. and Henkel, T. (2002)
Vectors systems for the heterologous expression of proteins in Saccharomyces cerevisiae. In Guide to Yeast Genetics and Molecular Cell Biology Part B, Methods in Enzymology, Vol 350: 248
Henkel, T. (1999) Therapeutic Innovation. IDrugs 2(5):403-404
Henkel, T. & Klein, H.-G. (1998) Differentielle Genexpression. Medizinische Genetik 2:356
Hsieh, J.J.D, Henkel, T., Salmon, P., Robey, E., Peterson, M.G. and Hayward, S.D. (1996) Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr Virus EBNA-2. Mol. Cell. Biol. 16, 952-959
Traenckner, E.B.M, Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S. and Baeuerle, P.A. (1995) Phosphorylation of human IκB- on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14, 2876-2883
Henkel, T., Ling, P.D., Hayward, S.D. and Peterson, M.G. (1994) Mediation of Epstein-Barr Virus EBNA2 trans-activation by Recombination Signal-Binding Protein Jκ. Science, 265, 92 - 95.
Baeuerle, P.A. and Henkel, T. (1994) Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12, 141-179.
Groß, N. A., Henkel, T., Karabinos, A., Götz, H., Barnikol-Watanabe, S. and Hilschmann, N. (1994) Human protein NEFA, a novel DNA binding/EF-hand/ leucine zipper protein - Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol. Chem. Hoppe Seyler, 375, 497-512
Machleidt, T., Wiegmann, K., Henkel, T., Schütze, S., Baeuerle, P. and Krönke, M.
(1994), Sphingomyelinase activates proteolytic IκB-a degradation in a cell-free system.
J. Biol. Chem. 269, 13760-13765
Henkel, T., Machleidt, T., Alkalay I., Krönke M., Ben-Neriah, Y. and P.A. Baeuerle
(1993) Rapid proteolysis of IκB- is necessary for activation of transcription factor NF-κB. Nature 365, 182-185
Zabel, U., Henkel, T., dos Santos Silva, M. and Baeuerle, P.A. (1993) Nuclear uptake
control of NF-κB by MAD-3, an IκB protein present in the nucleus. EMBO J. 12, 201-211
Henkel, T., Schmitz, M.L. and Baeuerle, P.A. (1993) Rapid characterization of lambda cDNA clones after amplification and radioactive labeling with the PCR technique. BioTechniques, 14 (6), 3 - 4
Henkel, T and P.A. Baeuerle (1993) Functional analysis of mutated cDNA clones by direct use of PCR products in in vitro transcription/translation reactions. Anal. Biochem. 214, 351-352
Henkel, T., Zabel, U., van Zee, K., Müller, J., Fanning, E. and Baeuerle, P.A. (1992) Intramolecular masking of the nuclear location signal and dimerization domain in the precursor of the p50 NF-κB subunit. Cell 68, 1121-1133
Ruben, S., Dillon, P.J., Schreck, R., Henkel, T., Chen, C.-H., Maher, M., Baeuerle, P.A. and Rosen C. (1991). Isolation of a rel- related human cDNA that potentially encodes the 65-kD subunit of NF-κB Science 251: 1490-1493
Patents:
Method for identifying substances directed against myocardial cell hypertrophy
PCT/WO 02/097128A2 published 05.12. 2002
Inventors: T. Henkel, V. Rönicke, B. Navé
Applicant: MediGene AG
Herz- und Skelettmuskelspezifische Nukleinsäure, ihre Herstellung und Verwendung.
German Patent issued 15.6. 2000
Inventors: T. Henkel, M. Hofmann & H. Domdey
Applicant: MediGene AG
Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
PCT/EP97/02840 filed 30.05 1997
Inventors: B. Steipe, H. Bruhn, M. Funk, T. Henkel
Applicant: MediGene AG
Epstein-Barr virus transcription factor binding assay
US Patent 5,679,525 issued 21.10. 1997
Inventors: T. Henkel & M. G. Peterson
Applicant: Tularik Inc.
Process for inhibiting the transcription of genes
US Patent 6,090,542 issued 18.7. 2000
Inventors: T. Henkel & P.A. Bäuerle
Applicant: Boehringer Ingelheim International GmbH et al.
Josef Rüschoff
Chief Medical Officer & Co-Founder
About
Research and Publications
Prof. Josef Rüschoff
Chief Medical Officer
Co-Founder
Prof. Rüschoff’s experience and passion for clinical pathology ensures that Targos biomarker research & development lead to innovation in clinical diagnostic routine. Prof. Rüschoff has played a leading role in the Targos efforts when supporting the approval of breakthrough diagnostic tests such as Her2 or PD-L1, which have become a cornerstone of Targos outstanding pathology quality.
Research and Publications
Research and Publications:
Diagnostic focus
- tumor pathology
- Gastrointestinal pathology
- Gynecological pathology
- spec. Breast pathology
- molecular pathology
Certificates
- "Optional advanced training in molecular pathology"
- "Gynecological preventive cytology"
- "Mommy screening"
Memberchip
Board member of the Academy for Continuing Education in Pathology
Honor
1990 Habilitation thesis awarded the research prize of the Hessian Cancer Society
Publications
Key publications
MSI related
1. Validation and introduction of the MSI testing primer panel
Dietmaier W,….Rüschoff J. Cancer Res 57:4749-56, 1997
Adopted by NCI
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004
2. Providing the first evidence that Aspirin is suppressing the MSI phenotype in vitro
Rüschoff J et al. PNAS 95: 11301-6, 1998
confirmed by R. Fishel using COX2 specific NSAR drugs
McIlhatton MA, Tyler J, Burkholder S, Rüschoff J, Rigas B et al. Cancer Res 67:10966-75, 2007
Based on these data it has recently been shown that Aspirin effectively suppresses tumors in Lynch Syndrome
Burn J et al. Lancet 378: 2081-7, 2011
HER2 receptor analysis
1. HER2 testing within HERA trial as central reference lab:
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, …, Rüschoff J, Suto T et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-72, 2005
2. HER2 testing within ToGA trial (Herceptin in Gastric cancer) with validation of a specially adapted scoring system as proposed by our group (Hofmann et al. Histopathology 52:797-805, 2008)
Bang Y-J,Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K for the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy for the treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. Lancet 376:687-97, 2010
Based on these experiences international recommendations for Her2 testing in gastric cancer have been published: Rüschoff J.et al. Mod Pathol 25(5):637-650, 2012
Reinhard Büttner
Chief Scientific Officer & Co-Founder
About
Prof. Dr. med. R. Büttner
Chief Scientific Officer
Co-Foundert
Prof. Büttner’s concurrent work as Director of Pathology at the University of Cologne enables him to support Targos in its pursuit of becoming a leader in cutting-edge technology for molecular pathology in clinical research & development. Moreover, Professor Reinhard Büttner has successfully implemented NGS technology into health care diagnostic routine for lung cancer.
Gudrun Bänfer
Head of Advance - Training & Consulting
About
Publications
Heinmöller, P., Bänfer, G., Grzelinski, M., Alexander K.V., Alexander, K.A., Jasani, B. (2018), Quality control of Immunohistochemical and In Situ Hybridization predictive biomarkers for patient treatment: Experience from international guidelines and international quality control schemes. In: Predictive biomarkers in Oncology, Badve, S. Kumar, G.L. (Ed.)
Scheel, A.H., Bänfer, G., et al. (2018), Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer Histopathology. 72(3):449-459.
Weising K., Guicking D., Fey-Wagner, C., Kröger-Kilian, T., Wöhrmann T., Dorstewitz, W., Bänfer G., Moog U., Vogel, M., Blattner, F.R., Fiala, B. (2010) Mechanisms of Speciation in Southeast Asian Ant-Plants of the Genus Macaranga (Euphorbiaceae). In: Glaubrecht M. (eds) Evolution in Action. Springer, Berlin, Heidelberg
Bänfer, G., Moog, U., Fiala, B., Mohamed, M., Weising, K. und Blattner, F. R. (2006), A chloroplast genealogy of myrmecophytic Macaranga species (Euphorbiaceae) in Southeast Asia reveals hybridization, vicariance and long-distance dispersals, Molecular Ecology 15, 4409-4424.
Bänfer, G., Fiala, B. und Weising, K. (2004), AFLP analysis of phylogenetic relationships among myrmecophytic species of Macaranga (Euphorbiaceae) and their allies. Plant Systematics and Evolution 249(3-4), 213-231.
Vogel, M., Bänfer, G., Moog, U. und Weising, K. (2003), Development and characterization of chloroplast microsatellite markers in Macaranga (Euphorbiaceae), Genome 46, 845-85
Blattner, F. R., Weising, K., Bänfer, G., Maschwitz, U. und Fiala, B. (2001), Molecular analysis of phylogenetic relationships among Myrmecophytic macaranga species (Euphorbiaceae), Molecular Phylogenetics and Evolution 19, 331-344.
Dr. Gudrun Bänfer
Head Targos Advance
Training & Consulting
With a background in science and project management, Dr. Bänfer has shaped the Targos Advance Training Program since 2010 to become a successful international pathology network today. This training program has a profound global presence, as 3.500 international pathologists were trained in the use of biomarker assays in oncology such as Her2, PD-L1, and NGS. The Targos Advance Program fulfills the mission of introducing highly standardized biomarkers to clinical routines.
Publications
Publications:
Heinmöller, P., Bänfer, G., Grzelinski, M., Alexander K.V., Alexander, K.A., Jasani, B. (2018), Quality control of Immunohistochemical and In Situ Hybridization predictive biomarkers for patient treatment: Experience from international guidelines and international quality control schemes. In: Predictive biomarkers in Oncology, Badve, S. Kumar, G.L. (Ed.)
Scheel, A.H., Bänfer, G., et al. (2018), Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer Histopathology. 72(3):449-459.
Weising K., Guicking D., Fey-Wagner, C., Kröger-Kilian, T., Wöhrmann T., Dorstewitz, W., Bänfer G., Moog U., Vogel, M., Blattner, F.R., Fiala, B. (2010) Mechanisms of Speciation in Southeast Asian Ant-Plants of the Genus Macaranga (Euphorbiaceae). In: Glaubrecht M. (eds) Evolution in Action. Springer, Berlin, Heidelberg
Bänfer, G., Moog, U., Fiala, B., Mohamed, M., Weising, K. und Blattner, F. R. (2006), A chloroplast genealogy of myrmecophytic Macaranga species (Euphorbiaceae) in Southeast Asia reveals hybridization, vicariance and long-distance dispersals, Molecular Ecology 15, 4409-4424.
Bänfer, G., Fiala, B. und Weising, K. (2004), AFLP analysis of phylogenetic relationships among myrmecophytic species of Macaranga (Euphorbiaceae) and their allies. Plant Systematics and Evolution 249(3-4), 213-231.
Vogel, M., Bänfer, G., Moog, U. und Weising, K. (2003), Development and characterization of chloroplast microsatellite markers in Macaranga (Euphorbiaceae), Genome 46, 845-85
Blattner, F. R., Weising, K., Bänfer, G., Maschwitz, U. und Fiala, B. (2001), Molecular analysis of phylogenetic relationships among Myrmecophytic macaranga species (Euphorbiaceae), Molecular Phylogenetics and Evolution 19, 331-344.
Petra Heinmöller
Director of Quality Management
About
Dr. Petra Heinmöller
Director Quality Management
The team led by Dr. Heinmöller supervises the compliance of all Targos processes in accordance with Good Clinical Practice and US-CAP and CLIA requirements. Data generated by Targos for Drug & Companion Diagnostic approvals have been successfully submitted to the FDA and EMA. Dr. Heinmöller has structured QM at Targos to comply successfully with many dozens of inspections and audits.
Bharat Jasani
Director of Pathology
About
Prof. Dr. Bharat Jasani
Director Pathology
Prof. Jasani‘s forty years of wide experience in academic pathology and biomarker research in Cardiff, UK, helped Targos to significantly enhance its internal pathology department, which he is leading since 2015. Recently he is driving vigorously digital pathology development for multiplex IHC and Immunofluoresence applications at Targos.
Dirk Zielinski
Head of Assay Development
About
Dr. Dirk Zielinski
Head of Assay Development
Dr. Zielinski started in 2003 with scientific work on signal transduction proteins as clinical biomarkers.
Since then he has helped to establish and validate several hundred biomarkers according to GCP and US-CAP / CLIA standards.
Meanwhile he is leading a strong Assay Development Team to respond to the challenges of the increasing demand for multiplex assays and digital pathology evaluation in immune therapy clinical trials.
Oliver Stoss
Director of Service Operations, President Targos Inc.
About
Dr. Oliver Stoss
Director Service Operations
As a skilled scientist and informatician, Dr. Stoss has structured and managed Targos processes since 2005 up to today’s level of quality and flexibility. Dr. Stoss is a versed leader and intelligently has developed the Targos service portfolio to the current breadth and depth.
